Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome

Adicet Bio, Inc.

FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
Patient enrollment for IIM/SPS cohort expected to start Q1 2025; Phase 1 now covers six autoimmune diseases.
Phase 1 program has four arms: LN/SLE, SSc, AAV, and combined IIM/SPS cohort.
Initial clinical data from Phase 1 in autoimmune diseases expected first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.